ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Financial Statements and ExhibitsItem 9.01 of the Original 8-K to present certain carve-out financial statements of the Therapy Business Unit and to present certain unaudited pro forma combined financial statements of the Company required to be filed in connection with the completion of the Acquisition.
| Item 9.01. | Financial Statements and Exhibits |
| (a) | Financial Statements of Business Acquired |
The audited carve-out balance sheets of the Therapy Business Unit as of December 31, 2016 and 2015 and the related audited carve-out statements of operations, changes in invested equity and cash flows for each of the two years in the period ended December 31, 2016, together with the notes thereto and the independent auditors’ reports thereon, are filed herewith as Exhibit99.1 hereto and are incorporated herein by reference.
The unaudited condensed carve-out balance sheets of the Therapy Business Unit as of March 31, 2017 and December 31, 2016 and the related unaudited condensed carve-out statements of operations, changes in invested equity and cash flows for the three-month periods ended March 31, 2017 and 2016, together with the notes thereto, are filed herewith as Exhibit99.2 hereto and are incorporated herein by reference.
| (b) | Pro Forma Financial Information |
The unaudited pro forma combined balance sheet of the Company as of March31, 2017 and the related unaudited pro forma combined statements of operations of the Company for the year ended December31, 2016 and the three months ended March31, 2017, together with the notes thereto, are filed as Exhibit 99.3 hereto and are incorporated herein by reference.
| (c) | Shell Company Transactions |
Not applicable.
See Exhibit Index.
ADMA BIOLOGICS, INC. ExhibitEX-23.1 2 e616382_ex23-1.htm Exhibit 23.1 CONSENT OF INDEPENDENT AUDITOR We consent to the incorporation by reference of our report dated March 14,…To view the full exhibit click here
About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.